Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

NCT03041181 is registered in ClinicalTrials.gov with Nasser Hanna, M.D. as lead sponsor.

NCT NCT03041181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03041181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Lead sponsor
Nasser Hanna, M.D.
Phase
Phase 2
Overall status
Terminated
Start date
January 27, 2017
Completion date
May 23, 2019
Enrollment
3 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung, lung cancer, non-squamous non-small cell lung cancer (nsclc), squamous cell lung cancer